Oncotrace RGCC is used to identify a primary tumour in a patient and to provide guidance about disease progression and future prognosis.

The Oncotrace test is an important tool for managing and following up on cancer treatment plans. In the early stages of cancer diagnosis, in addition to providing current circulating tumor cell (CTC) values, it can also detect cancer stem cell (CSC) markers to analyze the metastatic spread of these cells.

By analyzing cancer behavior at the molecular level, doctors and patients can monitor tumor marker activity related to metastasis, proliferation, drug resistance and metastatic spread.